LUPIN LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,845 INR | +0.70% |
|
+1.70% | +39.35% |
| 06:01am | Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences | MT |
| 07-15 | Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection | MT |
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-08-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,832
INR
Average target price
1,631
INR
Spread / Average Target
-10.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.35% | 10B | |
| +63.05% | 856B | |
| +38.96% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +13.83% | 244B | |
| +5.03% | 234B | |
| +16.22% | 226B | |
| +14.63% | 177B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences
